海思科(002653.SZ)：环泊酚注射液获得FDA上市批准

智通财经06-01

智通财经APP讯，海思科(002653.SZ)发布公告，公司全资子公司美国海思科(Haisco-USA Pharmaceuticals Inc.)于近日收到美国食品药品监督管理局(FDA)的上市批准通知，公司自主研发的环泊酚注射液(英文通用名：Cipepofol Injection，中文商品名：思舒宁®，英文商品名：CYPSEDO)在美国的新药上市申请(New Drug App lication，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640117980?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-01 11:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640117980","market":"sh","top_or_hot":-1,"title":"海思科(002653.SZ)：环泊酚注射液获得FDA上市批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，海思科(002653.SZ)发布公告，公司全资子公司美国海思科(Haisco-USA Pharmaceuticals Inc.)于近日收到美国食品药品监督管理局(FDA)的上市批准通知，公司自主研发的环泊酚注射液(英文通用名：Cipepofol Injection，中文商品名：思舒宁®，英文商品名：CYPSEDO)在美国的新药上市申请(New Drug App lication，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1448359.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>海思科(002653.SZ)：环泊酚注射液获得FDA上市批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n海思科(002653.SZ)：环泊酚注射液获得FDA上市批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-01 11:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1448359.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，海思科(002653.SZ)发布公告，公司全资子公司美国海思科(Haisco-USA Pharmaceuticals Inc.)于近日收到美国食品药品监督管理局(FDA)的上市批准通知，公司自主研发的环泊酚注射液(英文通用名：Cipepofol Injection，中文商品名：思舒宁®，英文商品名：CYPSEDO)在美国的新药上市申请(New Drug App lication，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1448359.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0033","symbol_name":"西藏振兴","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1448359.html","article_id":"2640117980","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640117980","pubTimestamp":1780285935,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，海思科 发布公告，公司全资子公司美国海思科于近日收到美国食品药品监督管理局的上市批准通知，公司自主研发的环泊酚注射液在美国的新药上市申请获得批准，用于成人全身麻醉诱导。国际化方面，环泊酚注射液于2021年获得FDA的IND申请批准，在美国直接进入关键Ⅲ期临床试验。在完成全部临床研究后其新药上市申请于2025年7月获得FDA受理，最终于近日获得FDA上市批准。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0033":"西藏振兴","BK4585":"ETF&股票定投概念","IPOS":"Renaissance International IPO ETF","BK0028":"国家队","BK0239":"医药制造","BK0077":"质押式回购","BK4588":"碎股","BK0188":"融资融券","002653":"海思科","LABU":"三倍做多标普生物-Direxion"},"translate_title":"Haisco (002653.SZ): Cypofol injection received FDA marketing approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"LABU":1.5,"002653":1.5},"content_text":"智通财经APP讯，海思科(002653.SZ)发布公告，公司全资子公司美国海思科(Haisco-USA Pharmaceuticals Inc.)于近日收到美国食品药品监督管理局(FDA)的上市批准通知，公司自主研发的环泊酚注射液(英文通用名：Cipepofol Injection，中文商品名：思舒宁®，英文商品名：CYPSEDO)在美国的新药上市申请(New Drug App lication，NDA)获得批准，用于成人全身麻醉诱导。环泊酚注射液是公司自主开发的全新具有自主知识产权的1类静脉麻醉药物，属于GABAA受体激动剂。该产品于2020年12月在中国获批上市，目前已在国内获批“非气管插管手术/操作中的镇静和麻醉”“全身麻醉诱导和维持”“重症监护期间的镇静”及“儿童/青少年全身麻醉诱导和维持”等多项适应症，市场份额稳步增长。国际化方面，环泊酚注射液于2021年获得FDA的IND申请批准，在美国直接进入关键Ⅲ期临床试验。在完成全部临床研究后其新药上市申请(NDA)于2025年7月获得FDA受理，最终于近日获得FDA上市批准。海外多个关键Ⅲ期临床试验结果显示，环泊酚注射液用于全身麻醉诱导起效迅速、术后苏醒快，且在血压稳定性、注射痛发生率等方面相比丙泊酚注射液具有临床优势。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640117980","isCrawlerRequest":true}